Immuneering reports Q2 net loss $14.1M; Fast Track for IMM-1-104; initial Phase 2 data expected 2H 2024

Immuneering Corp

2024-Q2 EPS reported -$0.96

Net loss $14.1M ($0.47/share) vs $12.2M ($0.43) in Q2 2023.
Cash $59.7M as of June 30, 2024; expected cash runway into 2H 2025.
FDA granted Fast Track designation for IMM-1-104 in first-line pancreatic cancer.
Initial data from multiple arms of IMM-1-104 Phase 2a trial expected in 2H 2024.
Initial PK/PD/safety data for IMM-6-415 Phase 1 expected in 2H 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.